|Bid||51.45 x 2200|
|Ask||51.53 x 3100|
|Day's range||50.30 - 51.64|
|52-week range||38.82 - 61.71|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||11.62|
|Forward dividend & yield||1.60 (3.19%)|
|Ex-dividend date||28 Jul 2022|
|1y target est||N/A|
NEW YORK & MAINZ, Germany, June 25, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1 variant of concern. Data from the Phase 2/3 trial found that a booster dose of both Omicron-adapted
NEW YORK, June 24, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Thursday, July 28, 2022. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2022 Performance Report, to be issued that morning.
NEW YORK, June 23, 2022--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 third-quarter 2022 dividend on the company’s common stock, payable September 6, 2022, to holders of the Common Stock of record at the close of business on July 29, 2022. The third-quarter 2022 cash dividend will be the 335th consecutive quarterly dividend paid by Pfizer.